LOGIN  |  REGISTER
Astria Therapeutics
Terns Pharmaceuticals

Biodesix to Participate in Upcoming Investor Conferences

May 21, 2025 | Last Trade: US$0.47 0.02 -5.01

LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences:

22nd Annual Craig-Hallum Institutional Investor Conference
1x1 Meetings
Date: Wednesday, May 28, 2025
Location: Minneapolis, MN

45th Annual William Blair Growth Stock Conference
Presentation and 1x1 Meetings
Date and Time: Wednesday, June 4, 2025 at 9:20 AM CT
Location: Chicago, IL

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at biodesix.com.

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com.

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Contacts:

Media:
Natalie St. Denis
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-720-925-9285

Investors:
Chris Brinzey
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-339-970-2843

Terns Pharmaceuticals

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page